Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)

B.O. Khatri, J. Pelletier, L. Kappos, H.P. Hartung, G. Comi, F. Barkhof, P. von Rosenstiel, X. Meng, A. Grinspan, R. Hashmonay, J.A. Cohen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)355-363
JournalMultiple Sclerosis and Related Disorders
Volume3
Issue number3
DOIs
Publication statusPublished - 2014

Cite this